- A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma — Recruiting • Phase III • Oncology • NCT05100862.
- What is being tested: Zanubrutinib (a Bruton tyrosine kinase inhibitor) combined with obinutuzumab (anti-CD20 monoclonal antibody) versus the standard regimen of lenalidomide plus rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma, with progression-free survival as the primary outcome measure.
- Patient eligibility overview: Adults with follicular lymphoma or marginal zone lymphoma that has progressed after or become resistant to prior treatment, representing a treatment-resistant population requiring alternative therapeutic strategies.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival…
- Key Inclusion Criteria: * Histologically confirmed grade 1-3a FL or MZL * Previously treated with ≥ 1 line of systemic therapy including anti-CD20 agent. Must have a documented failure to achieve at least partial response during the most recent systemic therapy or documented progressive disease after the most recent systemic therapy * Need for systemic therapy for FL or MZL * Measurable disease by computed tomography or magnetic resonance imaging * Adequate bone marrow, liver and renal function Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.